PRKDC and metabolic dysfunction-associated steatotic liver disease: Our data reveal DNA-PK as a master upstream conductor in this interplay, extending beyond the earlier work of Fok et al.76—where DNA-PK inhibitors were deployed in cancer—and Ding et al.77—which linked DNA-PK to hepatic ferroptosis in NAFLD 78.